Skip to main content
Homepage
No report run on this ticker yet Only preliminary foundational data below
For AI assistants & researchers — machine-readable summary of this page

What this page is: Delvantic's full research page for Oric Pharmaceuticals Inc. (ORIC) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.

Page map (sections in order; each card carries a stable reference-name attribute you can cite):

  • profile-header / price-overview — company profile, live quote, market cap
  • extended-analysis — the core: three AI lens reads with findings, scores, and the analyst memo
  • future-predictions — our forward price-band predictions
  • market-narrative / ai-findings / gpt-critique — narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)
  • Members-only sections (render as login gates for anonymous readers): price-history, income-trend, key-metrics, financials (statement tables), insider-trading. The analysis above is public; the raw data tables require a free account.

More for machine readers: site briefing at /llms.txt · any ticker resolves at delvantic.com/stock/TICKER · raw inputs are public-company filings and market data (via licensed data feeds); every model, score, lens read, and prediction on this page is Delvantic's own analysis.

Oric Pharmaceuticals Inc.

ORIC NASDAQ GICS Category PDF
Healthcare · Biotechnology
South San Francisco, CA 94080, United States oricpharma.com Updated Jul 30, 5:56am
Price
$11.28
Market Cap
$1.2B
Employees
104
Beta
1.01
Avg Volume
1,707,201
CEO
Dr. Jacob M. Chacko M.B.A., M.D.

Oric Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that address mechanisms of therapeutic resistance in cancer. The company targets innate, acquired, and bypass resistance to overcome limitations in existing cancer treatments, with a particular emphasis on hormone-dependent cancers, key tumor dependencies, and precision oncology. Its lead clinical-stage product candidates include rinzimetostat (ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 under investigation in Phase 1b studies for metastatic castration-resistant prostate cancer, often in combination with androgen receptor inhibitors, and enozertinib (ORIC-114), a brain-penetrant, orally bioavailable irreversible inhibitor targeting EGFR exon 20 insertion mutations, atypical EGFR mutations including PACC, and HER2 exon 20 mutations in non-small cell lung cancer patients, demonstrating systemic and central nervous system activity. Oric Pharmaceuticals Inc. maintains ongoing Phase 1b trials for these candidates, either as monotherapy or in combinations, and holds clinical development collaborations with partners such as Pfizer, Bayer, and Johnson & Johnson. Founded in 2014 and headquartered in South San Francisco, California, the company plays a significant role in advancing oncology innovations against resistance challenges.

Runs with full report
Earnings Schedule
Checked daily · calendar updated Jul 30
No upcoming print on the calendar yet — companies typically confirm a few weeks ahead. Last print was Jul 23, 2026.
Print date EPS est. EPS actual Revenue est. Revenue actual
Jul 23, 2026 $3.32 $3.52 +6.0% — —
May 4, 2026 $-0.32 $-0.34 -6.3% — —
Feb 23, 2026 $-0.37 $-0.30 +18.9% — —
Nov 13, 2025 $-0.40 $-0.33 +17.5% — —
Aug 12, 2025 $-0.44 $-0.47 -6.8% — —

Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.

Recent SEC Filings
Last updated: Jul 30, 2026 5:56am (3h ago)
Filed Form Document
Jul 28, 2026 4 View
Jul 8, 2026 4 View
Jul 6, 2026 144 View
Jul 6, 2026 144 View
Jun 22, 2026 8-K View
May 15, 2026 SCHEDULE 13G/A View
May 15, 2026 SCHEDULE 13G/A View
May 15, 2026 SCHEDULE 13G/A View
May 15, 2026 SCHEDULE 13G View
May 12, 2026 SCHEDULE 13G/A View
May 4, 2026 10-Q View
May 4, 2026 8-K View

Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.

Price Overview
Last updated: Jul 30, 2026 9:13am (just now)
Current data · timestamped when a report runs
$11.28
Change · Jul 30
-0.63 (-5.29%)
Day Range
$11.01 – $11.99
52-Week Range
$7.23 – $14.93
50-Day MA
$9.52
200-Day MA
$10.60
Volume
1,834,304.00
Share Structure
Outstanding 103,486,412.00
Float 82,717,778.00
Free Float 79.9%
Normal free float — 79.9% of shares trade freely, ~20.1% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Last updated: Jul 30, 2026 5:56am (3h ago)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Last updated: Jul 30, 2026 5:56am (3h ago)
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
TD Twelve Data statement HEX SEC filing
P/E Ratio (Price per dollar of earnings)
HEX
Stock Price / EPS (Diluted)
-7.67
Stock Price: $11.28
EPS (Diluted): -1.47
P/B Ratio (Price vs net asset value)
HEX
Stock Price / Book Value Per Share
2.58
Stock Price: $11.28
Total Equity: $384.36M
Shares: 87,793,801
EV/EBITDA (Total value vs operating profit)
HEX
Enterprise Value / EBITDA
-7.91
Market Cap: $1.17B
Total Debt: $0.00
Cash: $45.67M
EBITDA: -$141.78M
Enterprise Value (Takeover price (cap + debt - cash))
HEX
Market Cap + Total Debt - Cash
$1.1B
Market Cap: $1.17B
Total Debt: $0.00
Cash: $45.67M
Gross Margin (Revenue left after direct costs)
HEX
Gross Profit / Revenue
—
Gross Profit: N/A
Revenue: N/A
Missing from API: Gross Profit, Revenue
Operating Margin (Revenue left after all operations)
HEX
Operating Income / Revenue
—
Operating Income: -$143.00M
Revenue: N/A
Missing from API: Revenue
Net Margin (Revenue left as actual profit)
HEX
Net Income / Revenue
—
Net Income: -$129.47M
Revenue: N/A
Missing from API: Revenue
ROE (Profit from shareholder equity)
HEX
Net Income / Total Equity
-33.7%
Net Income: -$129.47M
Total Equity: $384.36M
ROIC (Profit from all invested capital)
HEX
NOPAT / Invested Capital
-42.2%
Operating Income: -$143.00M
Tax Rate: 0.0%
Equity: $384.36M
Total Debt: $0.00
Cash: $45.67M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
HEX
Current Assets / Current Liabilities
14.13
Current Assets: $288.47M
Current Liabilities: $20.42M
Debt/Equity (Leverage — debt vs equity)
HEX
Total Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $384.36M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
HEX
Revenue / Shares Outstanding
—
Revenue: N/A
Shares: 87,793,801
Missing from API: Revenue
Book Value/Share (Net assets per share)
HEX
(Total Assets - Total Liabilities) / Shares
$4.38
Total Equity: $384.36M
Shares: 87,793,801
FCF/Share (Real cash generated per share)
HEX
(Operating Cash Flow + CapEx) / Shares
$-1.27
Operating CF: -$110.97M
CapEx: -$712,000
Shares: 87,793,801
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
TD
Last Annual Dividend / Stock Price
—
Last Dividend: $0.00
Stock Price: $11.28
Payout Ratio (Earnings paid out as dividends)
HEX
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$129.47M
Dividends paid not available in cash flow statement
Income Statement (Annual)
Last updated: Jul 30, 2026 5:56am (3h ago)
Metric 2021 2022 2023 2024 2025
Revenue — — — — —
Cost of Revenue — — — — —
Gross Profit — — — — —
Operating Expenses $78.9M $91.8M $110.8M $142.9M $143.0M
Operating Income -$78.9M -$91.8M -$110.8M -$142.9M -$143.0M
Net Income -$78.7M -$89.1M -$100.7M -$127.8M -$129.5M
EBITDA -$78.0M -$90.8M -$109.7M -$141.8M -$141.8M
EPS $-2.07 $-2.25 $-1.96 $-1.83 $-1.47
EPS (Diluted) $-2.07 $-2.25 $-1.96 $-1.83 $-1.47
Balance Sheet (Annual)
Last updated: Jul 30, 2026 5:56am (3h ago)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $226.0M $66.8M $23.4M $59.4M $45.7M
Total Current Assets $240.5M $210.5M $212.6M $262.3M $288.5M
Total Assets $298.6M $247.2M $252.0M $274.1M $408.9M
Current Liabilities $15.2M $15.4M $20.5M $24.8M $20.4M
Long-Term Debt $10.5M — — — —
Total Liabilities $25.7M $24.8M $27.9M $31.0M $24.5M
Total Equity $273.0M $222.4M $224.1M $243.1M $384.4M
Retained Earnings -$245.1M -$334.2M -$434.9M -$562.8M -$692.2M
Cash Flow (Annual)
Last updated: Jul 30, 2026 5:56am (3h ago)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow -$59.5M -$75.1M -$85.7M -$112.7M -$111.0M
Capital Expenditure $-939,000 -$2.1M $-849,000 -$1.2M $-712,000
Free Cash Flow -$60.5M -$77.2M -$86.5M -$113.9M -$111.7M
Acquisitions (net) — — — — —
Net Debt Issued / (Repaid) — — — — —
Dividends Paid — — — — —
Stock Buybacks — — — — —
Net Change in Cash $148.0M -$159.2M -$43.4M $36.0M -$13.7M
Growth Trends (YoY %)
Last updated: Jul 30, 2026 5:56am (3h ago)
Metric 2022 2023 2024 2025
Revenue Growth — — — —
Gross Profit Growth — — — —
Operating Income Growth -16.4% -20.7% -29.0% -0.1%
Net Income Growth -13.2% -13.0% -27.0% -1.3%
EBITDA Growth -16.5% -20.9% -29.2% +0.0%
Industry Benchmarks
Compares ORIC against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Advanced Analysis Forensic deep-dive · three lenses
A separate, manually-run forensic pipeline (dilution, earnings quality, liquidity → two scored lenses → the play). Hasn't been run for this ticker yet.
Character & Durability Scorecard
Ten long-horizon business-character traits the Quality / Value / Sentiment lenses don’t break out, scored 1–10.
No scorecard yet for ORIC — the ten traits are scored by the pipeline (ext-scorecard step) when a report is run on this ticker.
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for ORIC — it's generated by the pipeline (market-narrative step).
Delvantic AI Findings
Claude Opus reviews the pipeline's raw data + every prior verdict, then writes an independent take.
Reviews the pipeline's own verdicts
No AI findings yet for ORIC — they're generated by the pipeline (ai-findings step) when a report is run on this ticker.
GPT Critique
GPT reads the same briefing + Delvantic AI Findings and writes its own take, agreeing or disagreeing with specific claims.
Reviews the Opus findings above
No GPT critique yet for ORIC — it's generated by the pipeline (gpt-critique step) after the AI findings above, when a report is run on this ticker.
Community AI Feedback
No community reviews yet for ORIC. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · twelvedata
v1.1.496 · 31f2d85f · 2026-07-29 20:18:08